Antiretroviral-drug resistance among patients recently infected with HIV.

By S. Little, S. Holte, J. Routy, E. Daar, M. Markowitz, A. Collier, R. Koup, J. Mellors, E. Connick, B. Conway and 5 more. New England Journal of Medicine, 2002

1,120 citations recorded by the source corpus.

Subfields: Infectious Diseases, Virology

View Paper: https://www.semanticscholar.org/paper/16c3e2e30eb28480fdb4904d8bc8a2050a63aeb0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Westby
2. C. Smith-Burchnell
3. P. Farmer
4. A. Wood
5. S. Keshavjee
6. Bruce Nizeye
7. B. Stammen
8. David A. Price

Citations in the corpus

• Structural Violence and Clinical Medicine (2006, background): “The program in Baltimore was improved in part by linking an understanding of social context to clinical services. The importance of such programs is underscored by the emergence of multidrug-resistant HIV in the United States [”
• Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity (2005, background): “As the incidence of drug-resistant variants in the treated HIV-infected population has increased, so has the transmission of drug-resistant virus to treatment-naive individuals (17, 20, 22, 52, 53).”